Silexion Gains Israeli Approval for Phase 2/3 Trial of KRAS-Targeting Therapy in Pancreatic Cancer
Event summary
- Silexion Therapeutics received approval from the Israeli Ministry of Health to initiate a Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer.
- The trial is expected to begin in Q2 2026, following positive preclinical results and completed toxicology studies.
- SIL204 targets KRAS mutations, present in over 90% of pancreatic cancers, with potential applicability across multiple cancer indications.
- The company plans to submit additional regulatory filings in Germany by Q2 2026 and across the EU in early 2027.
The big picture
Silexion's approval marks a critical step in advancing RNAi therapies for KRAS-driven cancers, an area with significant unmet medical need. The strategic focus on pancreatic cancer, followed by colorectal and lung cancers, aligns with the growing emphasis on precision oncology. Success in this trial could validate Silexion's integrated systemic treatment delivery approach, potentially attracting partnerships or investment.
What we're watching
- Trial Execution
- Whether Silexion can initiate the Phase 2/3 trial as planned in Q2 2026 and achieve timely patient enrollment.
- Regulatory Expansion
- The pace at which Silexion secures additional regulatory approvals in Germany and the broader EU.
- Therapeutic Potential
- How SIL204's broad KRAS mutation targeting could position it as a leading therapy across multiple cancer indications.
Related topics